Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.34 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338454 | 0.89 | DGAT2 (0.41) | DGAT2CNR2HTR4RORCHIF1A | |
| SCHEMBL4319243 | 0.89 | DGAT2 (0.44) | DGAT2CNR2HTR4RORCHIF1A | |
| SCHEMBL4318960 | 0.89 | DGAT2 (0.52) | DGAT2CNR2HTR4RORCEPAS1 | |
| SCHEMBL4319062 | 0.87 | RORC (0.42) | DGAT2CNR2HTR4RORC | |
| SCHEMBL4323561 | 0.87 | HIF1A (0.46) | DGAT2CNR2HTR4HIF1AEPAS1 | |
| SCHEMBL4339631 | 0.85 | DGAT2 (0.41) | DGAT2CNR2HTR4RORCHIF1A | |
| SCHEMBL4327073 | 0.84 | MAP2K3 (0.54) | DGAT2CNR2HTR4RORCANO1 | |
| SCHEMBL4341697 | 0.84 | DGAT2 (0.46) | DGAT2CNR2RORCANO1 | |
| SCHEMBL4326426 | 0.84 | DGAT2 (0.46) | DGAT2CNR2HTR4RORC | |
| SCHEMBL4325053 | 0.84 | DGAT2 (0.39) | DGAT2CNR2HTR4RORCHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | DGAT2 2919/4885CNR2 1/4885HTR4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.